Nordics: Difference between revisions
Updated |
Added new company |
||
| Line 14: | Line 14: | ||
|- | |- | ||
| [[Nolla Health]] || AI Dermatology || $4.5M || Launched in US | | [[Nolla Health]] || AI Dermatology || $4.5M || Launched in US | ||
|- | |||
| [[Actithera]] || Radiopharma / Radioligand Therapy || $75.5M Series A || Pipeline development | |||
|- | |- | ||
| [[Dignio]] || Remote Patient Monitoring || Acquired by [[Summa Equity]] || NHS pilot in UK | | [[Dignio]] || Remote Patient Monitoring || Acquired by [[Summa Equity]] || NHS pilot in UK | ||
|- | |- | ||
| [[Holberg EEG]] || AI Neurodiagnostics || Acquired by Natus || Global autoSCORE launch | | [[Holberg EEG]] || AI Neurodiagnostics || Acquired by Natus || Global autoSCORE launch | ||
|- | |||
| [[Lioness Medtech]] || Portable MRI / Brain Imaging || N/A (partnership) || First portable MRI in Norway | |||
|- | |- | ||
| [[No Isolation]] || Social Impact Robots || Undisclosed || Deployed in UK+ | | [[No Isolation]] || Social Impact Robots || Undisclosed || Deployed in UK+ | ||
| Line 36: | Line 40: | ||
|- | |- | ||
| [[Mindler]] || Digital Mental Health || $8.7M || Acquired ieso UK, Medified FI | | [[Mindler]] || Digital Mental Health || $8.7M || Acquired ieso UK, Medified FI | ||
|- | |||
| [[Acorai]] || Cardiac Monitoring || €4.2M+ || FDA Breakthrough Device designation | |||
|- | |- | ||
| [[Dentio]] || AI Dental || $2.3M (a16z) || Early stage | | [[Dentio]] || AI Dental || $2.3M (a16z) || Early stage | ||
|- | |- | ||
| [[Cellcolabs]] || Stem Cell Manufacturing || $12M || Bryan Johnson-backed | | [[Cellcolabs]] || Stem Cell Manufacturing || $12M || Bryan Johnson-backed | ||
|- | |||
| [[Meela]] || Patient-Therapist Matching || €2.6M Seed || Gothenburg-based | |||
|- | |- | ||
| [[Sakura]] || B2B Mental Health || Pre-seed || Female-founded | | [[Sakura]] || B2B Mental Health || Pre-seed || Female-founded | ||
|- | |||
| [[TrialMe]] || Femtech / Clinical Trials || Undisclosed || Fixing gender gap in trials | |||
|- | |- | ||
| [[Loovi]] || Preventive Health || €1M || Early stage | | [[Loovi]] || Preventive Health || €1M || Early stage | ||
| Line 60: | Line 70: | ||
* [[Telehealth]] — [[Kry / Livi]], [[Dr. Dropin]], [[Dignio]] | * [[Telehealth]] — [[Kry / Livi]], [[Dr. Dropin]], [[Dignio]] | ||
* [[Preventive Health]] — [[Neko Health]], [[Loovi]], [[Cellcolabs]] | * [[Preventive Health]] — [[Neko Health]], [[Loovi]], [[Cellcolabs]] | ||
* [[Blood Tech]] — [[Actithera]], [[Acorai]], [[Cellcolabs]], [[BOOST Pharma]] | |||
== Ecosystem Notes == | == Ecosystem Notes == | ||
Sweden significantly ahead of Norway in digital health funding and unicorn creation. Norway more device/RPM focused; Sweden dominates AI-first health companies. a16z entering Nordics via [[Dentio]] signals US VC interest. | Sweden significantly ahead of Norway in digital health funding and unicorn creation. Norway more device/RPM focused; Sweden dominates AI-first health companies. Actithera's $75.5M Series A (largest Norwegian health raise) shows radiopharma attracting big capital. a16z entering Nordics via [[Dentio]] signals US VC interest. | ||
== Sources == | |||
See [[Publications]] for all source publications. | |||
== See Also == | == See Also == | ||
| Line 68: | Line 82: | ||
* [[:Category:Norway]] | * [[:Category:Norway]] | ||
* [[:Category:Sweden]] | * [[:Category:Sweden]] | ||
[[Category:Region]] | [[Category:Region]] | ||
Revision as of 16:06, 13 April 2026
Nordics
Norway, Sweden, Denmark, Finland — digital health hub.
Norway 🇳🇴
| Company | Category | Funding | Status |
|---|---|---|---|
| Noteless | AI Clinical Documentation | €3.5M Seed | Active, 3,000+ clinicians |
| Dr. Dropin | Digi-Physical Healthcare | €19.2M | Expanding to London |
| Nolla Health | AI Dermatology | $4.5M | Launched in US |
| Actithera | Radiopharma / Radioligand Therapy | $75.5M Series A | Pipeline development |
| Dignio | Remote Patient Monitoring | Acquired by Summa Equity | NHS pilot in UK |
| Holberg EEG | AI Neurodiagnostics | Acquired by Natus | Global autoSCORE launch |
| Lioness Medtech | Portable MRI / Brain Imaging | N/A (partnership) | First portable MRI in Norway |
| No Isolation | Social Impact Robots | Undisclosed | Deployed in UK+ |
| Journalia | AI Healthcare Admin | $1M | Early stage |
Sweden 🇸🇪
| Company | Category | Funding | Status |
|---|---|---|---|
| Neko Health | Preventive Health / AI Scanning | $260M ($1.8B val) | Clinics in Stockholm, London, NYC planned |
| Tandem Health | AI Clinical OS | €42.6M Series A | 200K+ NHS staff, 5 EU markets |
| Kry / Livi | Telehealth | $316M+ (~$2B val) | Profitable, 5 countries |
| Mindler | Digital Mental Health | $8.7M | Acquired ieso UK, Medified FI |
| Acorai | Cardiac Monitoring | €4.2M+ | FDA Breakthrough Device designation |
| Dentio | AI Dental | $2.3M (a16z) | Early stage |
| Cellcolabs | Stem Cell Manufacturing | $12M | Bryan Johnson-backed |
| Meela | Patient-Therapist Matching | €2.6M Seed | Gothenburg-based |
| Sakura | B2B Mental Health | Pre-seed | Female-founded |
| TrialMe | Femtech / Clinical Trials | Undisclosed | Fixing gender gap in trials |
| Loovi | Preventive Health | €1M | Early stage |
| Doctrin | Digital Primary Care | Undisclosed | New CEO, UK expansion |
| Min Doktor | Online Healthcare | €4.7M | Struggling to scale |
| BOOST Pharma | Cell Therapy | €3.1M+ | RoslinCT partnership |
Key Investors
See Investors for the full list. Key names: Kinnevik, Northzone, Alliance VC, Summa Equity, Novo Holdings.
Key Topics
- Soft Funding — Norwegian and EU grant programs
- AI Clinical Documentation — hottest subsector: Noteless, Tandem Health, Dentio
- Telehealth — Kry / Livi, Dr. Dropin, Dignio
- Preventive Health — Neko Health, Loovi, Cellcolabs
- Blood Tech — Actithera, Acorai, Cellcolabs, BOOST Pharma
Ecosystem Notes
Sweden significantly ahead of Norway in digital health funding and unicorn creation. Norway more device/RPM focused; Sweden dominates AI-first health companies. Actithera's $75.5M Series A (largest Norwegian health raise) shows radiopharma attracting big capital. a16z entering Nordics via Dentio signals US VC interest.
Sources
See Publications for all source publications.